EGFR and non-small cell lung carcinoma: These drugs are effective for treating advanced EGFR mutation-positive non-small cell lung cancer (NSCLC), especially in patients who harbor EGFR exon 21 L858R mutation (EGFRL858R) or exon 19 deletions (EGFRdel19).